Oral Phentolamine in Nonspecific Erectile Insufficiency
Authors: Grant Gwinup
Journal: Annals of Internal Medicine (1988)

Brief Reports15 July 1988Oral Phentolamine in Nonspecific Erectile InsufficiencyGrant Gwinup, MDGrant Gwinup, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-2-162 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn patients with erectile insufficiency, it is often difficult to find a definite cause for the problem when clinical vascular disease, neurologic deficiency, obvious psychological problems, and endocrine abnormalities, including diabetes, have been excluded. Such patients are usually categorized as suffering from non-specific erectile insufficiency. A major addition to the literature on treating erectile insufficiency was the finding that intercavernosal injection of vasoactive substances often produces a dramatic effect in patients with non-specific erectile insufficiency, as well as in those whose disease was suspected to have a more precise cause (1-2). The injection technique, however, is inconvenient and has produced...References1. Brindley G. Maintenance treatment of erectile impotence by cavernosal unstriated muscle relaxant injection. Br J Psychiatry. 1986;149:210-5. CrossrefMedlineGoogle Scholar2. Janosko E. Intracavernous self-injection of papaverine and regitine for the treatment of organic impotence. NC Med J. 1986;47:305-7. MedlineGoogle Scholar3. MoralesSurridgeMarshallFenemore ADPJ. Nonhormonal pharmacological treatment of organic impotence. J Urol. 1982;128:45-7. CrossrefMedlineGoogle Scholar4. Brindley G. Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatry. 1983; 143:332. CrossrefMedlineGoogle Scholar5. Fleiss J. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons; 1981:117-9. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From the University of California, Irvine, Medical Center, Orange, California. For the current author address, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySleep-Related Painful Erections: A Meta-Analysis on the Pathophysiology and Risks and Benefits of Medical TreatmentsTreatment of Erectile DisorderMale Sexual FunctionA Preclinical Study of Novel Phentolamine Formulation and in Vitro/in Vivo EvaluationMechanisms of Penile Erection and Basis for Pharmacological Treatment of Erectile DysfunctionTreatment Options for Erectile DysfunctionSection I: Psychological InterventionsOutcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)Phentolamine relaxes human corpus cavernosum by a nonadrenergic mechanism activating ATP-sensitive K+ channelAetiology and Management of Male Erectile Dysfunction and Female Sexual Dysfunction in Patients with Cardiovascular DiseasePharmacotherapy of erectile dysfunctionThe Hemodynamics of Erection and the Pharmacotherapies of Erectile DysfunctionCavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy men and patients with erectile dysfunctionGuidelines on Erectile DysfunctionPharmacological Aspects of Erectile DysfunctionPhentolamine mesylate relaxes rabbit corpus cavernosum by a nonadrenergic, noncholinergic mechanismA Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile DysfunctionOral and injectable medications for the treatment of erectile dysfunctionErectile Dysfunction: Diagnosis and Management with Newer Oral AgentsErectile DysfunctionEmerging pharmacological therapies for erectile dysfunctionOral pharmacotherapy for erectile dysfunction: current perspectivesPharmacotherapeutic Advances in the Treatment of Erectile DysfunctionOral phentolamine and female sexual arousal disorder: A pilot studyMedical treatment of erectile dysfunctionCombination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunctionORAL PHENTOLAMINE AS TREATMENT FOR ERECTILE DYSFUNCTIONOral treatment of erectile dysfunction: From herbal remedies to designer drugsORAL PHENTOLAMINE AS TREATMENT FOR ERECTILE DYSFUNCTIONNew oral therapies for the treatment of erectile dysfunctionOral, Transdermal, and Transurethral Therapies for Erectile DysfunctionCurrent Status of Noninvasive Pharmacological Therapy for Erectile DysfunctionOral treatments for erectile dysfunctionORAL AND TOPICAL TREATMENT OF ERECTILE DYSFUNCTIONPharmacology of erection: Agents which initiate and terminate erectionFactors predicting efficacy of phentolamine-papaverine intracorporeal injection for treatment of erectile dysfunction in diabetic maleEffects of Intracavernosal Trazodone Hydrochloride: Animal and Human Studies 15 July 1988Volume 109, Issue 2Page: 162-163KeywordsEndocrinologyVascular diseases Issue Published: 15 July 1988 PDF downloadLoading ...